The Vascular Disease Research Center
at Rhode Island Hospital
Does Safe Thrombus Removal In DVT have an Effect on Patient Outcomes? (STRIDE-1)
Deep vein thrombosis (DVT) occurs in up to 300,000 Americans yearly and carries high cost and morbidity. Current treatment does not adequately address the long-term damage clots cause to veins. Up to 60 percent of patients develop chronic leg symptoms as a result. Studies suggest that rapid clot removal may decrease these long-term problems in addition to more quickly relieving acute pain and swelling.
The purpose of the STRIDE-1 clinical trial is to evaluate the safety and effectiveness of a minimally invasive, catheter-based approach (the Trellis-8 device) for the removal of blood clots from the veins in the legs. The Trellis-8 device is approved by the FDA for this purpose and is available commercially. This device is currently the percutaneous treatment of choice at our institution for appropriate patients.
Patients presenting with clinical manifestations of acute DVT of the lower extremity (pain, swelling, signs of decreased blood-flow) who meet inclusion criteria will be selected and followed for thirty days post-treatment.
Back | Ongoing Studies
|
